Oncology trial design is being rewritten. The endpoints, eligibility criteria and regulatory expectations that shaped protocols 18 months ago are no longer sufficient for the science being tested today.

In this webinar, Estelle Guiheneuf, Head of Oncology at TFS HealthScience, joined  Dr Emiliano Calvo, Director of Early Phase Clinical Trials at START Madrid, to work through what has actually changed and what it means for protocols in development now.

Download the slide deck to explore:

— The new endpoints: ctDNA, MRD, advanced imaging biomarkers and patient-reported outcomes, and where each strengthens decision-making rather than adding complexity
— The eligibility conversation: how performance status, age and biomarker stratification are being rethought across major tumour types
— What good looks like in practice: how to build a protocol that takes advantage of the science without inflating site burden or regulatory risk

Prefer to watch the full conversation? The one-hour replay is available to registered attendees. Register here to access it.